Gland Pharma Limited — Q3 FY24
Gland Pharma reported consolidated revenue of INR 1,545 crore in Q3 FY24, up 65% YoY, driven by the Cenexi acquisition and strong US base business growth of 17% YoY.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY24
Base business EBITDA margin target of 30-32%
Management expects base business EBITDA margins to remain in the 30-32% range, with potential slight decline as lower-margin Enoxaparin supplies resume.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY24
Cenexi revenue run rate of EUR 50-55 million per quarter
CFO guided that Cenexi's normalized quarterly revenue should be around EUR 50-55 million on a full quarter basis.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY24
Steady sequential revenue growth for base business
Management expects steady quarter-on-quarter growth in the base business, driven by new launches and volume expansion.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1